Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion 0 12.09.2020 22:31 The Wall Street Journal The biotech drugmaker has a market value of roughly $10 billion, meaning that Gilead would be paying up for the company and its prized breast-cancer drug. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
